Trial reportDigestive diseases and sciences2013
Comparison between botulinum injection and removable covered self-expanding metal stents for the treatment of achalasia.
Trial report in Digestive diseases and sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- ACG Clinical Guidelines: Diagnosis and Management of Achalasia.The American journal of gastroenterology · 2020Guideline
- European guidelines on achalasia: United European Gastroenterology and European Society of Neurogastroenterology and Motility recommendations.United European gastroenterology journal · 2020Guideline
- Gastrointestinal Uses of Botulinum Toxin.Handbook of experimental pharmacology · 2021Trial
- Long-term efficacy of modified retrievable stents for treatment of achalasia cardia.Surgical endoscopy · 2016Trial
- Evaluating the Non-conventional Achalasia Treatment Modalities.Frontiers in medicine · 2022Review
- Safety and efficacy of biodegradable stents in octogenarian patients with esophageal achalasia.Endoscopy international open · 2021Article
- Effects of preoperative endoscopic pneumatic balloon dilatation on postoperative achalasia symptoms after Heller esophageal myotomy plus Dor fundoplication.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018Article
- Self-expandable metal stent placement in a child for treatment of achalasia after failed Heller myotomy.Endoscopy international open · 2018Article
- Observational
- Review
- Self-expandable metal stents for achalasia: Thinking out of the box!World journal of gastrointestinal endoscopy · 2015Review
- Treatment implications of high-resolution manometry findings: options for patients with esophageal dysmotility.Current treatment options in gastroenterology · 2014Article
- Achalasia: a review of clinical diagnosis, epidemiology, treatment and outcomes.World journal of gastroenterology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntrasphincteric injection of botulinum toxin (BTX) and removable self-expanding metal stents (SEMS) have both been used for the treatment of achalasia.
aimTo compare the effectiveness and long-term outcome of SEMS placement and BTX injection in patients with achalasia.
methodsA total of 110 patients with newly diagnosed achalasia were enrolled in the study between July 2003 and December 2009. The patients received either BTX injection (n = 51) or SEMS placement (n = 59). Clinical symptoms, objective parameters, and long-term clinical outcomes were evaluated after 7 and 30 days and then every 6 months until withdrawal from the study. The mean duration of follow-up was 28 months (range 10-36 months).
resultsImprovements in global symptom and dysphagia scores and in basal lower esophageal sphincter pressure were significantly more marked in the SEMS group than in the BTX group (all P < 0.05). After 12 months, the remission rate in the SEMS group (81.28 %) was statistically significantly higher than that in the BTX group (64.58; P < 0.05). At 36 months, the remission rates in the two groups were 49.1 and. 4.2 %, respectively (P < 0.01). The symptom-free interval was 831 ± 46 days in the SEMS group and 522 ± 42 days in the BTX group (P < 0.01). No side effects were reported with BTX treatment. In the SEMS group there were 13 episodes of chest pain, nine cases of regurgitation, and four stent migrations. No serious complications occurred.
conclusionRemovable SEMS was associated with better long-term outcomes than BTX injection in patients with achalasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.